What is the recommended usage and dosage of Flexeril (cyclobenzaprine) for treating muscle spasms?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 13, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Cyclobenzaprine (Flexeril) Dosage and Usage for Muscle Spasms

The recommended dosage of cyclobenzaprine for most adult patients with muscle spasms is 5 mg three times daily, which may be increased to 10 mg three times daily based on individual response. Use should not exceed two to three weeks. 1

Standard Dosing Regimen

  • For most adult patients, the standard dose is 5 mg three times daily 1
  • Based on individual patient response, the dose may be increased to 10 mg three times daily 1
  • Lower doses (5 mg) are as effective as higher doses (10 mg) with fewer side effects, particularly sedation 2
  • Extended-release formulations are available as once-daily dosing (15 mg and 30 mg) 3, 4

Duration of Treatment

  • Use of cyclobenzaprine for periods longer than two to three weeks is not recommended 1
  • Clinical trials have demonstrated efficacy within 3-4 days of treatment initiation 2
  • Improvements in muscle spasm, pain relief, and increased range of motion are typically observed within the first week of treatment 2, 4

Special Populations

  • For elderly patients, less frequent dosing should be considered due to increased risk of anticholinergic effects and sedation 1
  • For patients with hepatic impairment, start with 5 mg and titrate slowly upward 1
  • Cyclobenzaprine is not recommended for patients with moderate to severe hepatic insufficiency due to lack of data 1
  • The American Geriatrics Society Beers Criteria identifies cyclobenzaprine as potentially inappropriate for older adults due to anticholinergic effects and sedation 5

Mechanism and Clinical Uses

  • Cyclobenzaprine is a centrally acting skeletal muscle relaxant structurally related to tricyclic antidepressants 5
  • It is primarily indicated for relief of muscle spasm associated with acute, painful musculoskeletal conditions 5
  • Clinical studies have demonstrated efficacy for both neck and low back pain with associated muscle spasm 2, 3

Side Effects and Monitoring

  • Most common side effects include drowsiness (dose-related), dry mouth, dizziness, and constipation 2, 4
  • Anticholinergic effects include hallucinations, confusion, drowsiness, constipation, urinary retention, and dry mouth 6
  • Lower doses (5 mg TID) are associated with fewer side effects than higher doses (10 mg TID) while maintaining similar efficacy 2
  • Extended-release formulations may be associated with less daytime drowsiness compared to immediate-release formulations 3, 4

Discontinuation

  • For patients using cyclobenzaprine long-term, implement a gradual taper over 2-3 weeks to prevent withdrawal symptoms 6, 5
  • Abrupt discontinuation after prolonged use can lead to withdrawal symptoms including malaise, nausea, and headache 6, 5

Important Precautions

  • Cyclobenzaprine has potential to interact with sedatives and anesthetic agents 6
  • Perioperative management guidelines recommend holding cyclobenzaprine on the day of surgery 6, 5
  • Avoid concomitant use with monoamine oxidase inhibitors due to risk of serotonin syndrome 6
  • Combination therapy with NSAIDs like ibuprofen has not shown superior efficacy compared to cyclobenzaprine alone 7

Comparative Efficacy

  • Cyclobenzaprine has been evaluated in numerous clinical trials and has consistently been found effective for acute muscle spasm 8
  • It has similar efficacy to diazepam for muscle spasm but with different side effect profiles (more dry mouth with cyclobenzaprine, more dizziness with diazepam) 1
  • Cyclobenzaprine's efficacy is independent of its sedative effects, as patients who did not report somnolence still showed significant improvement 2

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.